A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Updates from The Motley Fool

Latest updates on Geron from Fool.com.


Stock Performance

GERN vs. S&P 500 | 2 Year Performance
View Interactive GERN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Geron.
Current Price: $2.27
Prev Close: $2.26
Open: $2.30
Bid: $2.24
Ask: $2.35
Day's Range: $2.25 - $2.35
52wk Range: $1.84 - $5.30
Volume: 1,176,056
Avg Vol 2,426,654
Market Cap: $359.16M
P/E (ttm): 226.00
EPS (ttm): $0.01
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Geron.
CAPS Rating 3 out of 5
 
647 Outperform
60 Underperform
CAPS All Stars
 
87 Outperform
16 Underperform

How do you think Geron will perform against the market?



You pick for Geron is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John A. Scarlett, CEO

100% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Geron.

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers